Recently, ATP9A was shown to be required for the recycling pathway from the endosome to the plasma membrane and to mediate Wntless sorting, Wnt secretion and exosome release [
26–
28], indicating that ATP9A may be involved in cellular vesicle transport. However, the regulatory mechanism of ATP9A in mammalian endosomal transport is still unknown.
Endocytic recycling is the major pathway to maintain the abundance of receptors and transporters on the cell surface and is critical for several important cellular processes such as cell migration and cytokinesis as well as the maintenance of polarity in neurons [
29]. Endocytic recycling is the process by which cargo molecules are transported from the cell surface into RAB5-positive early endosomes and recycled directly back to the plasma membrane (fast recycling) or subsequently delivered to RAB11-positive recycling endosomes, which release them outside the plasma membrane (slow recycling) [
30]. Dysregulation of the expression and activity of the small GTPases RAB5 and RAB11 leads to disruption of endosomal recycling and has been linked to a variety of diseases, including cancer and central or peripheral neurological disorders [
31–
33].
Here, for the first time, we successfully recapitulated human neurological disease phenotypes in an ATP9A knockout mouse model and found that ATP9A deficiency causes synaptic dysfunction in primary motor cortex and hippocampus. Further studies suggest that the underlying pathogenic mechanism involves inactivation of RAB5 and RAB11. Our work highlights the critical role of ATP9A in maintaining synaptic function associated with endosome trafficking and creates a new animal model that simulates human hypotonia, ID, and ADHD disorders.